Neuroendocrinology · 2015 · 55 citations · 36 references
MedicineOncologyPharmacologyCancer PharmacologyEndocrine OncologyMolecular OncologyCancer BiomarkersLung CancerMalignant NeoplasmsNeuroendocrine Tumor TherapyNeuroendocrine TumorsClinicopathological CorrelationDopamine Receptor SubtypesImmunohistochemical BiomarkersImmunohistochemical MarkersPulmonary Carcinoid TumorsPulmonary Neuroendocrine TumorsSomatostatin AnaloguesSomatostatin Receptor Expression
OBJECTIVE: The expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance as somatostatin analogues and dopamine agonists can be used for their localization and/or treatment. The objective of this study is to examine the expression of the five SSTR subtypes and DR2 in lung carcinoids (LCs). METHODS: We conducted a retrospective study of 119 LCs from 106 patients [typical carcinoids (TCs): n = 100, and atypical carcinoids (ACs): n = 19]. The expression of all five SSTR subtypes and DR2 was evaluated immunohistochemically and correlated to clinicopathological data. In a subgroup of cases, receptor expression was further analyzed using semiquantitative RT-PCR. RESULTS: SSTR2A was the SSTR subtype most frequently expressed immunohistochemically (72%), followed by SSTR1 (63%), SSTR5 (40%), and SSTR3 (20%), whereas SSTR4 was negative. DR2 was expressed in 74% and co-expressed with SSTR1 in 56%, with SSTR2A in 59%, with SSTR3 in 19%, and with SSTR5 in 37% of the tumors. Receptor expression was not related to the histological subtype, tumor aggressiveness (disease extent/grading) or functionality; however, DR2 was expressed more frequently in ACs than TCs (95 vs. 70%, p = 0.017). In a subset of patients, RT-PCR findings highly suggested that the expression of SSTR2A, SSTR3, DR2, and to a lesser extent that of SSTR1 and SSTR5 is the outcome of increased gene transcription. CONCLUSIONS: The high and variable immunohistochemical expression of the majority of SSTRs along with their co-expression with DR2 in LCs provides a rationale for their possible treatment with agents that target these receptors.
36
Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations
Medicine, Oncology, Pharmacotherapy +17
Guido Rindi, Günter Klöppel, Anne Couvelard et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2007 · 954 citations · Full text
William D. Travis, Walter L. Rush, Douglas B. Flieder et al. · The American Journal of Surgical Pathology · 1998 · 806 citations
Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text
Medicine, Oncology, Pharmacology +15